Stocks · News reference

Creative Medical Technology Acquires 4M Additional BioDefense Stock For $200K Cash And 1M Shares, Raising Ownership To 80%

Sep 25, 2026, 9:13 PMBenzinga Newsdesk

On September 24, 2026, Creative Medical Technology Holdings, Inc. (the "Company") entered into a Stock Purchase Agreement (the "Purchase Agreement") with Creative Acquisition Corp. ("CAC"),

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CELZ

Source: benzinga
Observed: Sep 25, 2026, 9:13 PM
Checked: Sep 25, 2026, 9:13 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

SEC EDGARSep 25, 2026, 9:00 PMSEC EDGAR
8-K filing — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Filed: 2026-09-25 AccNo: 0001477932-26-005805 Size: 163 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
CELZ
BenzingaSep 17, 2026, 1:06 PMBenzinga Newsdesk
Creative Medical Technology Announces Filing Of New US Provisional Patent Application To Expand IP Protection Surrounding Ultrasome, Its Proprietary Cell-Free Regenerative Medicine Platform
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the
CELZ
BenzingaAug 20, 2026, 6:24 PMBenzinga Newsdesk
Creative Medical shares are trading higher after the company announced that all patients have now been enrolled and treated across its FDA-cleared ADAPT clinical trial of CELZ-201 / Olastrocel, including the opioid expansion cohort.
CELZ

Creative Medical Technology Acquires 4M Additional BioDefense Stock For $200K Cash And 1M Shares, Raising Ownership To 80%

Connected Markets

Related Headlines

8-K filing — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

Creative Medical Technology Announces Filing Of New US Provisional Patent Application To Expand IP Protection Surrounding Ultrasome, Its Proprietary Cell-Free Regenerative Medicine Platform

Creative Medical shares are trading higher after the company announced that all patients have now been enrolled and treated across its FDA-cleared ADAPT clinical trial of CELZ-201 / Olastrocel, including the opioid expansion cohort.